Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, J. Wouter Jukema et al.|New England Journal of Medicine|2018Cited by 3.5k
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J. Raal, Daniel Gaudet, Robert S. Rosenson et al.|New England Journal of Medicine|2020Cited by 763
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialEvan A. Stein, Robert Pordy, Dan Gipe et al.|The Lancet|2012Cited by 579
ANGPTL3 Inhibition in Homozygous Familial HypercholesterolemiaDaniel Gaudet, G. Kees Hovingh, Daniel A. Gipe et al.|New England Journal of Medicine|2017Cited by 329
Evinacumab in Patients with Refractory HypercholesterolemiaRobert S. Rosenson, Daniel Gaudet, Lesley Burgess et al.|New England Journal of Medicine|2020Cited by 294